Cefotaxime in the treatment of infections of the skin and skin structure.
In a series of open, noncomparative studies, cefotaxime was given to 360 hospitalized patients with bacterial wound infections such as cellulitis, abscesses, or necrotizing ulcers of the skin or subcutaneous tissues. The drug was administered intramuscularly or intravenously in a mean dosage of 4 g per day (range, 1.4-12.0 g per day) in three or four equal doses for at least five days. Clinical response to therapy could not be evaluated for 100 patients, and bacterologic response could not be evaluated for 145 patients. Clinical response was satisfactory in 93.5% of the 260 patients for whom therapy could be evaluated, and bacterial response was satisfactory in 84% of the 225 patients for whom therapy could be evaluated. These rates of response include both single- and multiple-pathogen infections. There were nine instances of superinfection.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001424:Bacterial Infections / Q000175:diagnosis / Q000188:drug therapy*; D002439:Cefotaxime / Q000627:therapeutic use*; D002648:Child; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012874:Skin Diseases, Infectious / Q000188:drug therapy*; D014946:Wound Infection / Q000188:drug therapy*
D002439:Cefotaxime